MCL1 and neoplasm: In addition, the effect of doxorubicin can be augmented by OV-mediated MCL-1 downregulation with co-treatment significantly increasing tumor cell death (Figure 4B,C) [223].For several cancer types, doxorubicin-treated senescent tumor cells, which are resistant to more classical methods of treatment, were efficiently killed by an oncolytic measles virus [167].